• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BOT

BOTANIX PHARMACEUTICALS LTD - News & Media

0.00% ! 11.0¢
Market Cap $215.7M  !
Healthcare Biotechnology
Add to My Watchlist

Botanix (ASX:BOT) is an ASX-listed dermatology company based in Philadelphia and Phoenix... Botanix (ASX:BOT) is an ASX-listed dermatology company based in Philadelphia and Phoenix (USA), committed to the development of novel treatments for common skin diseases and infections.More

Articles & Videos

Maybe sweat the small stuff: Botanix underwhelms, falls -40%

The problem with building big valuation expectations on the treatment of rare diseases is that you either need expensive drugs, or, some kind of government support, because a rare disease, by its very nature, implies a small addressable market.Listen to the HotCopper podcast for in-depth discussi...

08 Jul 2025 11:22 (AEST)

First Sofdra prescriptions for excessive sweating condition pushes Botanix towards full commercial launch

Botanix has reported the first prescriptions of its drug Sofdra (sofpironium) to treat hyperhidrosis, a condition of excessive sweating.

17 Dec 2024 10:25 (AEDT)

US FDA approves Botanix Pharma's excessive underarm sweat drug

Botanix on Thursday described itself as having transitioned from a development stage to being revenue-generating dermatology company.

20 Jun 2024 10:56 (AEST)

Botanix isn't sweating on FDA approval for Sofdra

Botanix has submitted the last label materials to the FDA seeking approval for Sofdra™ a prescription treatment for underarm sweating.

12 Jun 2024 09:49 (AEST)

Botannix Pharmaceuticals' resubmission of Sofdra NDA accepted by FDA

Botannix Pharmaceuticals' (ASX:BOT) resubmission of the new drug application for Sofdra has been accepted by the FDA as a complete response.

22 Jan 2024 12:04 (AEDT)

Botanix Pharmaceuticals completes HF validation study for Sofdra, eyes FDA approval by mid-2024

Botanix Pharmaceuticals (ASX:BOT) has completed the planned human factors (HF) validation study for Sofdra, evaluating revised instructions for use (IFU).

14 Dec 2023 11:53 (AEDT)

FDA greenlights Botanix Pharmaceuticals' Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to Q1 CY2024.

04 Dec 2023 10:08 (AEDT)

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional and sophisticated investors to accelerate commercial activities in the US to increase revenue turnaround.

01 Dec 2023 11:50 (AEDT)

Botanix Pharmaceuticals (ASX:BOT) suffers setback in FDA approval for sofpironium bromide gel to treat hyperhidrosis

Botanix Pharmaceuticals (ASX:BOT) has had its application to use the novel sofpironium bromide gel to treat primary axillary hyperhidrosis rejected by the US FDA.

26 Sep 2023 16:36 (AEST)

Botanix Pharmaceuticals (ASX:BOT) appoints Dr Howie McKibbon as CEO

Botanix Pharmaceuticals (ASX:BOT) has appointed Dr Howie McKibbon as its newest Chief Executive Officer, effective from August 24. 

25 Aug 2023 11:17 (AEST)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
11.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $215.7M
Open High Low Value Volume
11.0¢ 11.5¢ 10.5¢ $1.671M 15.21M

Buyers (Bids)

No. Vol. Price($)
38 1999069 11.0¢
 

Sellers (Offers)

Price($) Vol. No.
11.5¢ 3491375 33
View Market Depth
Last trade - 16.10pm 11/09/2025 (20 minute delay) ?
Last
11.3¢ 		  Change
0.000 ( 1.72 %)
Open High Low Volume
11.5¢ 11.5¢ 10.5¢ 10963806
Last updated 15.59pm 11/09/2025 ?
BOT (ASX) Chart

Top Stories

Market Close: Aussie traders divorce from US as retreat continues. At least there's 4DX

Good Afternoon and welcome to HotCopper’s Market Close for Thursday 11th of September, I’m Jon Davidson. We’ve truly diverted from Wall Street at the start of September with the local bourse retreating once again this week, showing an Australian inv...
Listen: HotCopper Wire Podcast 024 – Two '4D' stocks to watch, but only one winner In this HotCopper Wire Week 37 episode, we take a look at the Coles and Woolies legal fight and compare 4DMedical and 4DS Memory.
EV Resources snaps up Nevada antimony project; will raise $5.5M for it, Los Lirios EV Resources has come out of its halt with a bang, unveiling the acquisition of the Dollar Antimony Project in Nye County alongside a raise.
EVR opens strong with funding, acquisition, and sales agreement announcements EVR has caught attention on the HotCopper forums and across the wider Australian markets today with a flurry of announcements.
Afterpay owner Block shares dip after competitor Klarna lists 30% higher out the gate Afterpay owner Block has seen its shares head towards a -3% drop as the market digests news of Klarna's successful U.S. IPO overnight.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.